Physicians will present three abstracts supporting the EyePoint Pharmaceuticals' Yutiq three-year micro-insert for noninfectious posterior segment uveitis July 25.
Here are three highlights:
1. The presentations will take place at the 36th Annual Scientific Meeting of the American Society of Retina Specialists in Vancouver, BC, Canada.
2. The three abstracts below will be delivered as part of the Inflammatory and Infectious Diseases Symposium:
- Durham, N.C.-based Duke Eye Center's Glenn J. Jaffe, MD, will present "Confirmatory 1-Year Study Results of an Injectable Fluocinolone Acetonide Intravitreal Insert to Treat Noninfectious Posterior Segment Uveitis."
- Stanford (Calif.) University's Quan Nguyen, MD, MSc, is scheduled to present "Controlling Uveitic Recurrences: Results From a Phase 3 Study of 0.18 mg Fluocinolone Acetonide Insert (FAi) in Noninfectious Posterior Uveitis."
- Sunil Srivastava, MD, of the Cleveland Clinic's Cole Eye Institute will present "Injectable Fluocinolone Acetonide Intravitreal Insert Reduces the Need for Adjunctive Treatment in Noninfectious Posterior Segment Uveitis."
3. The FDA is reviewing a new drug application for Yutiq for the treatment of noninfectious posterior segment uveitis, with a decision date of Nov. 5.
"Noninfectious posterior segment uveitis represents the third leading cause of blindness, and we believe that, if approved, Yutiq has the potential to serve as an important new treatment option for the thousands of patients suffering from this disease," said President and CEO Nancy Lurker.